Actavis Group, a global integrated specialist pharmaceutical company, has sold its shares in Actavis Pharma Manufacturing to Vivimed Labs for ₹1.22 billion (US$20 million). The shares were held by Actavis Group companies in the Netherlands.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.